AspenBio edges upward after "buy" rating
AspenBio Pharma Inc. (Nasdaq:APPY) is trading heavier than usual after Lazard Capital Markets started coverage of the medical and biotech company with a “buy” rating. In midday trading Tuesday, AspenBio shares rose 13.82% to $5.27 per share. The Castle Rock, Colo.-based company has long anticipated the FDA approval of the its new appendicitis screening test, and Lazard set a price target of $15 per share for AspenBio based on that approval.
For detailed price information and recent news stories about AspenBio Pharma, click APPY.
About the Author
Reporter Dianna Heitz is based in SmallCapInvestor.com's Washington, DC bureau.
Read More
(click a star)
Enter comment: